{"filings":[{"id":834356,"accession_number":"0001213900-26-064744","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-06-03T20:25:25+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics CFO Matthew Szot leaves; CEO Quang Pham takes interim CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Matthew K. Szot mutually agreed to step down effective May 28, 2026.","CEO Quang X. Pham appointed interim CFO and interim principal accounting officer.","Company is conducting a search for a permanent CFO to replace Szot.","Severance includes $365,806 severance, $237,903 FY2026 target bonus, and accelerated option vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96826,"accession_number":"0001213900-26-053075","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics Q1 net loss $2.5M; details Phase 3 plan for CAD-1005 in HIT","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.5M in Q1 2026 vs $3.8M in Q1 2025; operating expenses $2.5M vs $3.9M.","Cash $2.3M at March 31; subsequent $2.5M financing completed April 1, 2026.","Received FDA EOP2 meeting minutes; plans randomized, blinded, placebo-controlled Phase 3 trial in ~120 HIT patients.","Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005 added to standard anticoagulant therapy.","CAD-1005 is first-in-class 12-LOX inhibitor; holds FDA Orphan Drug and Fast Track designations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96825,"accession_number":"0001213900-26-049754","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal completes FDA End-of-Phase 2 meeting; gets guidance for Phase 3 pivotal trial of CAD-1005 in HIT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 2 data showed >25% absolute reduction in thrombotic events when CAD-1005 added to standard anticoagulant therapy.","Planned Phase 3 trial: randomized, blinded, placebo-controlled; ~120 patients at up to 50 sites worldwide.","Primary endpoint: incidence of new or worsening thrombotic events (centrally adjudicated) in SRA-confirmed HIT patients.","Projected NDA submission in 2029; first randomized, blinded, placebo-controlled registration trial in HIT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96824,"accession_number":"0001213900-26-038014","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Cadrenal Therapeutics receives $2.5M gross proceeds from warrant exercise, issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holder exercises 571,430 shares at reduced price of $4.50 per share, yielding $2.5M gross proceeds.","Company issues new Series B-1 (5-year term) and Series B-2 (18-month term) warrants to purchase 571,430 shares each at $4.50.","Placement agent H.C. Wainwright receives 7% cash fee ($175k) and warrants for 37,143 shares at $5.625.","Expected closing on April 1, 2026; net proceeds used for working capital.","Company agrees to file resale registration statement for new warrant shares within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111074,"accession_number":"0001213900-26-036937","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics reports Q4 net loss of $3.0M, cash $4.0M; CAD-1005 FDA EOP2 meeting completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $3.0M vs $4.2M YoY; R&D expenses $0.7M vs $1.5M; G&A $2.4M vs $2.7M.","Cash and equivalents $4.0M at Dec 31, 2025; evaluating financing and strategic alternatives to support clinical development.","Completed End-of-Phase 2 FDA meeting on March 26, 2026 for CAD-1005; Phase 3 pivotal trial protocol incorporation underway.","Phase 2 HIT study showed >25% absolute reduction in thrombotic events with CAD-1005 vs placebo on standard anticoagulation.","CAD-1005 has Orphan Drug and Fast Track designations from FDA; orphan status from EMA."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111073,"accession_number":"0001213900-26-026646","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal 12-LOX inhibitor CAD-1005 shows preclinical benefits in obesity and Type 2 diabetes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data: CAD-1005 improved glycemic control, reduced pancreatic β-cell loss, and lowered inflammatory cells in adipose/pancreatic tissues.","CAD-1005 also evaluated for HIT; Phase 2 trial reduced thrombotic events. Company acquired 12-LOX portfolio in Dec 2025.","Company believes CAD-1005 is the only clinical-stage 12-LOX inhibitor and may complement GLP-1 obesity drugs.","CEO highlights broader potential of 12-LOX inhibition beyond HIT; interested in partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111072,"accession_number":"0001213900-26-019606","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics Phase 2 HIT trial: primary endpoint missed, thrombotic events reduced >25%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Platelet count recovery (primary endpoint) did not differ between CAD-1005 and placebo arms.","Thrombotic events: >75% in placebo vs 50% in CAD-1005 group (>25% absolute reduction).","End-of-Phase 2 meeting with FDA scheduled for March 2026 to discuss Phase 3 path.","CAD-1005 is the only 12-LOX inhibitor in clinical development worldwide.","Trial concluded December 2025 after program transfer from Veralox Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127710,"accession_number":"0001213900-25-125433","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics files prospectus supplement for up to $1.77M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Already sold $10,005,300 in shares under the existing ATM agreement since March 2024.","New tranche of up to $1,770,028 of common stock through H.C. Wainwright as sales agent.","Commission of 3.0% of gross proceeds payable to Wainwright for its services.","Offer made under existing effective S-3 registration statement filed March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127709,"accession_number":"0001213900-25-121932","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics raises ~$2.2M in registered direct offering and private placement of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$2.2M from sale of 207,374 shares at $10.85 per share and warrants to purchase 414,748 shares.","Warrants immediately exercisable at $10.60/share, expire 2 years after effective date of resale registration statement.","Officers and directors subject to 10-day lock-up; company restricted from equity issuance for 10 days and variable rate transactions for one year.","Placement agent H.C. Wainwright receives 7% cash fee and 13,479 placement agent warrants at $13.5625/share.","Closing expected on or about December 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127708,"accession_number":"0001213900-25-120360","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.","VLX-1005 is a first-in-class, potent 12-LOX inhibitor with FDA Orphan Drug and Fast Track designations for HIT.","Phase 2 interim results demonstrated encouraging reductions in thromboembolic events; no deaths or serious AEs in Phase 1.","HIT affects ~56,000 confirmed diagnoses annually in the U.S.; current therapies do not address immune-driven pathogenesis.","Deal adds VLX-1005 to Cadrenal's anticoagulation pipeline alongside tecarfarin and frunexian, targeting $3B+ peak revenue potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127707,"accession_number":"0001213900-25-116307","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics appoints Dr. Lee Golden to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lee Scott Golden appointed independent Class II director effective Nov 24, 2025; term expires at 2027 annual meeting.","Golden is EVP and CMO of PTC Therapeutics (PTCT) with 25+ years in cardiovascular and hematologic drug development.","Golden serves on Science and Technology Committee; receives $35,000 annual fee plus equity awards.","Appointment aligns with Cadrenal's focus on advancing tecarfarin for anticoagulation unmet needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127706,"accession_number":"0001213900-25-112123","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics files prospectus supplement for up to $3.4M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to $3,438,062 of common stock via ATM program with H.C. Wainwright.","As of Nov 18, 2025, $9,386,964 of common stock already sold under the same ATM agreement dated March 11, 2024.","Wainwright will receive 3.0% commission on gross sales; Company has no obligation to sell shares.","Legal opinion from Blank Rome LLP attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127705,"accession_number":"0001213900-25-107949","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics Q3 2025 net loss $2.7M; advances tecarfarin and frunexian pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.7M for Q3 2025 vs $2.4M in Q3 2024; cash and equivalents $3.9M as of Sept 30.","R&D expense $0.7M (down from $0.8M); G&A expense $2.0M (up from $1.7M) year-over-year.","Completed cGMP manufacturing of tecarfarin; ongoing Phase 2 LVAD study with Abbott.","Acquired eXIthera Pharmaceuticals assets in Sept 2025, including frunexian, a Phase 2-ready IV Factor XIa inhibitor.","~2.1M common shares outstanding as of Sept 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144482,"accession_number":"0001213900-25-091109","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cadrenal Therapeutics elects Steven Zelenkofske as director; ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 2025 annual meeting, stockholders elected Steven Zelenkofske as Class III director with 669,494 votes for, 15,099 withheld.","Ratification of WithumSmith+Brown as FY2025 auditor passed with 1,207,152 votes for, 64,913 against, 12,681 abstain.","Broker non-votes of 600,153 on director election; none on auditor ratification (routine matter).","Meeting held September 24, 2025; quorum of 1,284,746 shares out of 2,046,854 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144481,"accession_number":"0001213900-25-087461","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors for up to $15M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires frunexian (Phase 2-ready IV FXIa) and EP-7327 (IND-ready oral FXIa) from eXIthera.","Total contingent milestone payments up to $15M plus royalties on global sales; $50K cash paid at closing.","Deal closed September 12, 2025; Cadrenal now sole developer of both a VKA (tecarfarin) and FXIa inhibitors.","Plans Phase 2 study for frunexian in complex cardiac surgery with first patient expected in 1Q27.","eXIthera to receive 2% royalty on net sales outside China and 50% of sublicense royalties from Haisco."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144480,"accession_number":"0001213900-25-074355","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal reports Q2 net loss $3.7M, cash $5.6M; plans tecarfarin trial in ESKD dialysis patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.7M for Q2 2025 versus $2.4M in Q2 2024; G&A increased to $2.7M from $1.2M.","Cash and equivalents $5.6M at June 30, 2025, down from $10.0M at December 31, 2024.","Plans to initiate clinical trial of tecarfarin in ESKD patients transitioning to dialysis; site activation expected later in 2025.","Completed technical transfer and cGMP manufacturing of tecarfarin drug substance at a U.S. CDMO site.","Added to Russell 3000E and Russell Microcap indexes effective June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144479,"accession_number":"0001213900-25-071764","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cadrenal to begin tecarfarin trial in ESKD patients transitioning to dialysis later this year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial includes ESKD patients with and without atrial fibrillation, enrollment planned to begin later this year.","Tecarfarin has orphan drug and fast-track designations for ESKD+AFib, highlighting unmet need.","Addresses critical gap: no proven anticoagulant for dialysis initiation period, which carries excess cardiovascular risk.","CEO Quang X. Pham calls the study an important step forward for tecarfarin development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144478,"accession_number":"0001213900-25-065710","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.02","5.08","8.01","9.01"],"status":"ready","headline":"Cadrenal director resigns; 2025 annual meeting set for Sept 24, proposal deadline July 28","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Robert Lisicki resigned from board effective July 15, 2025, with no disagreement with the company.","2025 annual meeting scheduled for September 24, 2025; record date for voting is July 28, 2025.","Shareholder proposals for proxy inclusion must be received by July 28, 2025; director nominations also due July 28.","Universal proxy rule: shareholders soliciting proxies for director nominees must provide notice by July 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162846,"accession_number":"0001213900-25-041049","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics Q1 net loss widens to $3.8M; cash at $7.3M; tecarfarin development advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M for Q1 2025 vs $1.7M in Q1 2024; R&D expense $1.7M (up from $0.6M), G&A $2.3M (up from $1.1M).","Cash and equivalents $7.3M at Mar 31, 2025, down from $10.0M at Dec 31, 2024; 1.9M common shares outstanding.","Appointed Dr. James Ferguson as CMO in February 2025 to lead clinical development and business development.","FDA Type D meeting in Feb 2025 provided guidance for Phase 3 tecarfarin trial; Abbott collaboration announced for TECH-LVAD trial.","Completed API manufacturing transfer from Asia to U.S. CDMO; LVAD market research projects near doubling by 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162845,"accession_number":"0001213900-25-032732","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics files ATM prospectus supplement for up to 2.17M shares; $7.7M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to 2,169,272 shares of common stock via ATM program with H.C. Wainwright.","Company had sold $7,655,240 in common stock under the existing ATM agreement as of the filing date.","Wainwright earns 3.0% commission on gross proceeds from any sales under the ATM agreement.","Company may suspend or terminate the offering at any time; no obligation to sell shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180792,"accession_number":"0001213900-25-023762","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics FY2024 net loss $10.7M; cash $10.0M; Abbott collaboration for Phase 3 tecarfarin trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.7M for FY2024 (vs $8.4M in 2023); G&A expenses nearly doubled to $6.8M.","Cash and equivalents of $10.0M as of Dec 31, 2024, up from $8.4M year-end 2023; ~1.8M shares outstanding.","Collaboration with Abbott (NYSE: ABT) to support pivotal Phase 3 TECH-LVAD trial of tecarfarin.","FDA Type D meeting in Feb 2025 provided guidance for tecarfarin Phase 3 trial design; FDA requested full study synopsis.","Appointed Dr. James J. Ferguson as CMO and Jeff Cole as COO; received ODD for tecarfarin in LVAD patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180791,"accession_number":"0001213900-25-019747","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics signs collaboration with Abbott to support Phase 3 LVAD trial of tecarfarin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abbott will share LVAD data from MOMENTUM 3 and ARIES HM3 trials for TECH-LVAD trial design.","Abbott to assist with biostatistics, site selection, patient enrollment, and medical science liaison.","Cadrenal is regulatory sponsor; tecarfarin-related IP owned by Cadrenal, device-related IP by Abbott.","Phase 3 TECH-LVAD trial compares tecarfarin vs warfarin in HeartMate 3 LVAD patients with open-label extension.","No upfront or milestone payments disclosed; Cadrenal still pursuing additional funding partnerships for the study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180790,"accession_number":"0001213900-25-011315","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cadrenal appoints James J. Ferguson as CMO; Dr. Douglas Losordo departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Ferguson, over 25 years cardiovascular experience, appointed Chief Medical Officer effective Feb 5, 2025.","Annual base salary of $505,000; discretionary bonus up to 40% of base; option grant of 60,000 shares.","Dr. Losordo separated amicably; severance includes 6-month salary continuation, bonus, and accelerated vesting.","Dr. Ferguson to lead late-stage clinical development of tecarfarin including pivotal LVAD trial.","Compensation includes option vesting: 25% on Mar 1, 2026, balance pro rata over 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197648,"accession_number":"0001213900-24-095195","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics Q3 2024 cash $11.3M, raises $9.8M from ATM and warrants","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 operating expenses $2.5M including $0.3M non-cash; cash used in operations $2.2M.","Raised $5.1M via ATM and $4.7M from warrant exercises, totaling $9.8M.","FDA discussions advancing on tecarfarin Phase 3 LVAD trial protocol; Abbott collaboration ongoing.","CDMO completed readiness to supply API and clinical trial materials under cGMP.","Joined Anticoagulation Forum Corporate Council to engage 15,000 healthcare professionals."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197647,"accession_number":"0001213900-24-094155","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Cadrenal raises $4.7M via warrant exercise; issues new warrants for additional shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised 285,715 existing warrants at reduced price of $16.50/share, generating ~$4.7M gross proceeds.","Issued new Series A-1 and A-2 warrants each to purchase 285,715 shares at $16.50/share as inducement.","Net proceeds to fund pivotal Phase 3 trial of tecarfarin and partnering activities.","H.C. Wainwright & Co. served as placement agent; receives 7% cash fee and 18,571 placement agent warrants.","New Series A-1 warrants expire in 5 years; Series A-2 expire 18 months after resale registration effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197646,"accession_number":"0001213900-24-090153","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics raises $5.1M via ATM facility, selling 391,243 shares at $13.15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.1M from sale of 391,243 shares at weighted avg price of $13.15/share.","Post-sale shares outstanding 1,496,771; cash balance approximately $7.4M as of Oct 23, 2024.","Proceeds to fund tecarfarin development and preparation for pivotal Phase 3 trial.","H.C. Wainwright acted as exclusive sales agent; shelf registration effective March 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213878,"accession_number":"0001213900-24-081799","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics posts updated presentation detailing Phase 3 plans for tecarfarin in LVAD and other indications","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial planned for LVAD patients: 440 patients randomized 1:1 tecarfarin vs warfarin for 26 weeks.","Tecarfarin has FDA Orphan Drug Designation for LVAD and ESKD+AFib, and Fast Track for ESKD+AFib.","Cash $5.0M, no debt, market cap $14.2M as of 9/18/24; insider ownership 42%.","Phase 2/3 data showed tecarfarin achieved higher TTR (70% vs 67%, p=0.04) and fewer thrombotic events than warfarin.","Presentation also outlines targeted indications: MHV patients with difficult-to-control TTR or warfarin resistance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213877,"accession_number":"0001213900-24-076144","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept 5 confirming closing bid price >=$1 for 10 consecutive business days (Aug 20-Sept 4).","Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the matter is closed.","No further action required; stock continues trading on Nasdaq Capital Market under CVKD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213876,"accession_number":"0001213900-24-070883","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq $1 minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 effective 12:01 a.m. ET on August 20, 2024; shares reduced from ~16 million to ~1.1 million.","No fractional shares issued; holders of fractional shares receive cash based on 10-day average closing price before effective time.","Split intended to bring common stock (CVKD) into compliance with Nasdaq's $1.00 minimum bid price requirement.","New CUSIP number for common stock is 127636207; proportional adjustments made to outstanding equity awards and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213875,"accession_number":"0001213900-24-069941","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics announces 1-for-15 reverse stock split effective Aug 20, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-15; effective at 12:01 a.m. ET on August 20, 2024.","Outstanding shares reduced from ~16M to ~1.1M; no fractional shares; cash paid in lieu.","New CUSIP number 127636 207; stock continues trading under CVKD on Nasdaq.","Split intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.","Proportional adjustments made to equity awards, warrants, and exercise prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213874,"accession_number":"0001213900-24-066613","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cadrenal Therapeutics Provides Q2 2024 Corporate Update and Financial Results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaborated with Abbott to advance tecarfarin for LVAD patients using HeartMate 3 device.","Received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in LVAD patients.","Q2 2024 operating expenses (ex-non-cash) totaled $2.3 million; cash used in operations was $1.5 million.","Cash balance as of June 30, 2024 was $5.0 million.","CEO Quang Pham highlighted progress on pivotal trial and LVAD study protocol development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213873,"accession_number":"0001213900-24-065400","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal partners with Abbott for pivotal tecarfarin trial in LVAD patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cadrenal (CVKD) and Abbott (ABT) initiate collaborative effort for tecarfarin pivotal trial in recently implanted LVAD patients.","Tecarfarin received FDA Orphan Drug Designation in April 2024 for preventing clots in mechanical circulatory support devices.","Only LVAD available in U.S. is Abbott's HeartMate 3; collaboration aims to improve anticoagulation outcomes.","Prior clinical data suggest tecarfarin yields better anticoagulation quality in LVAD-relevant populations (multiple meds, renal impairment)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213872,"accession_number":"0001013762-24-003209","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cadrenal stockholders approve reverse split, share increase, and equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved reverse stock split at Board's discretion (1:2 to 1:20 ratio).","Authorized share increase from 75M to 125M shares of common stock.","Equity plan amendment adds 2,000,000 shares (total 4,604,550) and modifies evergreen provision to 20% of outstanding plus warrant shares.","Elected directors John Murphy and Robert Lisicki to Class II until 2027.","Ratified WithumSmith+Brown as independent auditor for 2024 fiscal year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233094,"accession_number":"0001213900-24-040955","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.08","3.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics sets 2024 Annual Meeting for July 29, 2024; updates stockholder proposal deadlines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting scheduled for July 29, 2024; record date set as June 6, 2024.","Stockholder proposals under Rule 14a-8 must be received by May 20, 2024.","Director nominations and other proposals not included in proxy also due by May 20, 2024.","Universal proxy rule compliance notice due by May 30, 2024 (60 days before meeting)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233093,"accession_number":"0001213900-24-031371","cik":1937993,"company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cadrenal Therapeutics receives FDA Orphan Drug Designation for tecarfarin in VAD patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted ODD for tecarfarin to prevent thromboembolism/thrombosis in patients with LVADs, RVADs, biventricular assist devices, and total artificial hearts.","ODD provides up to 7 years of U.S. market exclusivity after approval, tax credits for clinical research, and NDA user fee waiver.","This is tecarfarin's second ODD; first was for prevention of systemic thromboembolism in ESKD/AFib patients.","Warfarin achieves target anticoagulation only 56% of the time in VAD patients; DOACs like Eliquis are not indicated for VADs.","Cadrenal CEO states company is dedicated to advancing tecarfarin through clinical development options as swiftly as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14255188.357723579,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}